HeartFlow Stock

heartflow.comHealthcareFounded: 2007Funding to Date: $528.88MM

HeartFlow is revolutionizing precision heart care, combining human ingenuity with advanced AI technology. The founders began their journey to improve coronary artery disease diagnosis and HeartFLow has now now expanded its product portfolio to include anatomic stenosis and plaque information. This company was founded by Charles Taylor, Christopher Zarins, and John Stevens in 2007 and is headquartered in Redwood City, CA.

Register for Details

For more details on financing and valuation for HeartFlow, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for HeartFlow.

Register Today

HeartFlow investors also invested in these private companies

Team

Management Team

Campbell Rogers MD
Chief Medical Officer & Executive Vice President
Charles Taylor Ph.D
Co-Founder, Chief Scientific Officer & Board Member
Noemi Espinosa JD
Chief Ethics & Compliance Officer & General Counsel
Christopher Zarins MD
Co-Founder, Senior Advisor on Clinical Science & Senior Vice President of Medical Affairs
John Farquhar
Chief Executive Officer, President & Board Member
Monica Tellado
Chief Financial Officer

Board Members

William Weldon
Board Member
Jeffrey Lightcap
HealthCor Partners Management
Lonnie Smith
Board Member
Casey Tansey
US Venture Partners
Barry Uphoff
Capricorn Investment Group

Other companies like HeartFlow in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$298.33MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$327.39MM
Sector
 
 
Sector
Last Round Est. Valuation
$500MM

News

For 2019, we asked companies around the world one basic question: “Please indicate the key technology which you believe will have the most profound impact on the healthcare industry during 2019?” The results are not very surprising:
The $1.5 billion health-tech startup HeartFlow has a noninvasive test for heart disease based on machine learning analysis of CT scans. Two new studies are unlikely to win over its critics.
The valuation is based on a big idea: a noninvasive test that peers into a patient’s coronary arteries to see how blocked they are.